Metraipolis › archive › dc_146ddc5eb405

Risk-based vaccination reveals marked heterogeneity in the clinical benefit of PCV20 — Europe PMC PPR:PPR1312670

Source
Europe PMC
Original
https://europepmc.org/article/PPR/PPR1312670
DOI
10.64898/2026.08.31.26361811
License (as archived)
CC0-1.0
Archived
2026-10-06T07:55:03.617Z
SHA-256 of the archived text
e935af681e770e8afdee96079b35cd0b3ff07e01b2612c04829ff60df708ab25
Stable URL of this page
https://metraipolis.com/documento/dc_146ddc5eb405

How to cite

Risk-based vaccination reveals marked heterogeneity in the clinical benefit of PCV20 — Europe PMC PPR:PPR1312670 — Europe PMC, https://europepmc.org/article/PPR/PPR1312670 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_146ddc5eb405 (Metraipolis archive dc_146ddc5eb405, sha256 e935af681e770e8afdee96079b35cd0b3ff07e01b2612c04829ff60df708ab25)
BibTeX
@misc{dc146ddc5eb405,
  title = {Risk-based vaccination reveals marked heterogeneity in the clinical benefit of PCV20 — Europe PMC PPR:PPR1312670},
  howpublished = {Europe PMC},
  url = {https://europepmc.org/article/PPR/PPR1312670},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_146ddc5eb405; sha256 e935af681e770e8afdee96079b35cd0b3ff07e01b2612c04829ff60df708ab25},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC, https://europepmc.org/article/PPR/PPR1312670. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Pneumococcal vaccination of older adults is primarily guided by age and clinical eligibility, despite substantial variation in individual risk of severe pneumonia. Here, we used longitudinal electronic health records from 787,538 adults aged ≥65 years to evaluate the real-world effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) and quantify clinical benefit according to baseline risk of pneumonia hospitalization. We developed and validated a machine-learning model using pre-PCV20 data to estimate individual 12-month hospitalization risk and integrated these predictions into a propensity score matching framework. Overall vaccine effectiveness against pneumonia hospitalization was 16.5% (95% CI, 10.6– 22.1), but this population-level estimate masked substantial heterogeneity in clinical benefit. The 60% at lowest predicted risk, characterized by younger age and fewer pulmonary and other chronic conditions, showed no measurable reduction in hospitalization (VE, 3.1%; 95% CI, −14.4 to 18.0) and had an estimated 1-year number needed to vaccinate (NNV) of 7,423, compared with 184 and 115 in the intermediate- and high-risk groups, respectively. These findings suggest that incorporating baseline risk into adult pneumococcal vaccination strategies could enable more targeted and potentially better-timed vaccination.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: medRxiv, 2026 (prima pubblicazione 2026-09-03).
Identificativi: DOI 10.64898/2026.08.31.26361811.
Pagina: https://europepmc.org/article/PPR/PPR1312670 — https://doi.org/10.64898/2026.08.31.26361811. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T07:47:50.126Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.